Skip to main content

Table 2 Information on donors—course of FQ treatment, symptoms of FQAD, effect of the experiment

From: Regeneration difficulties in patients with FQAD can limit the use of iPSc-based cell therapy

Record Age range FQ name/days of treatment/dose in mg per day Time since last FQ treatment ADR after FQ immediate/delayed FQAD symptoms constant/intermittent Test result
DONOR 1 30–39 Lev/9 days/500 mg 1 year Immediate Constant Failed/no adherence
DONOR 2 70–79 Lev/2 days/500 mg 10 years Immediate Constant Failed/no adherence
DONOR 3 50–59 Lev/7 days/500 mg 6 years Delayed Constant Failed/no adherence
DONOR 4 30–39 Cip/10 days/500 mg 1 year Delayed Constant Failed/senescence before reprogramming
DONOR 5 20–29 Cip/30 days/1000 mg 0.5 year Delayed Constant Failed/senescence before reprogramming
DONOR 6 30–39 Cip otic/10 days/3 mg 0.5 year Delayed Constant Failed/senescence before reprogramming
DONOR 7 40–49 Cip otic/10 days/6 mg 0.5 year Delayed Constant Failed/senescence before reprogramming
DONOR 8 60–69 Cip/10 days/ 1000 mg 10 years Delayed Constant Failed/senescence after reprogramming
DONOR 9 50–59 Lev /5 days/ 500 mg 9 years Delayed Constant Complete
DONOR 10 40–49 Lev/24 days/500 mg 5 years Delayed Constant Failed/senescence after reprogramming
  1. Cip Ciprofloxacin, Lev Levofloxacin